Filing Flows › Health Care › Kymera Therapeutics (KYMR)
Kymera Therapeutics (KYMR) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · Kymera Therapeutics (KYMR) Q2 2026 earnings results →
Q2 2026 Revenue up 466% year over year to $65.0M · 94¢ of every $1 of revenue lost · operating margin -116.3%
Kymera Therapeutics made $65.0M in Q2 2026 (+466% Y/Y). Operating margin -116.3%, net loss $61.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $65.0M in Q2 2026, up 466% year over year and up 89% from the previous quarter.
Operating costs exceeded revenue by $75.6M, an operating margin of -116.3%. Total costs grew 46% against revenue growth of 466%. The quarter ended with a net loss of $61.2M, narrower than the previous quarter's $69.2M loss. Non-operating items added $14.4M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$54.1M. Non-cash charges added back $2.0M of depreciation and amortization and $18.9M of share-based compensation. Working capital and other items used $13.8M. Capital expenditures of $473K exceeded it, leaving free cash flow of −$54.5M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $65.0M | +466% | -116.3% | −$61.2M | −$54.1M |
| Q1 2026 | 10-Q | Apr 30, 2026 | $34.4M | +56% | -244.9% | −$69.2M | −$88.8M |
| Q4 2025 | 10-K | Feb 26, 2026 | $2.9M | -61% | n/m | −$87.0M | −$66.7M |
| Q3 2025 | 10-Q | Nov 4, 2025 | $2.8M | -26% | n/m | −$82.2M | −$27.1M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $11.5M | -55% | -736.8% | −$76.6M | −$59.9M |
| Q1 2025 | 10-Q | May 9, 2025 | $22.1M | +115% | -336.8% | −$65.6M | −$79.2M |
| Q4 2024 | 10-K | Feb 27, 2025 | $7.4M | -85% | n/m | −$70.8M | −$61.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Kymera Therapeutics
We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients’ lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Our approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner.
In its own words, from its 10-K, filed Feb 26, 2026.
Kymera Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +466% against the peers' median +29%. Operating margin: -116.3% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| KYMR Kymera Therapeutics | Q2 2026 | $65.0M | +466% | -116.3% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Kymera Therapeutics 10-Q on SEC EDGAR · CIK 1815442 · Biological Products, (No Diagnostic Substances)
13F: who owns KYMR and who is buying
More on KYMR
- How Kymera Therapeutics makes money: revenue by segment
- Kymera Therapeutics next earnings date and what analysts expect
- Kymera Therapeutics stock forecast, price target and fair value
- Who owns Kymera Therapeutics stock: holders, funds and Congress trades
- Kymera Therapeutics recalls, complaints and regulation
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results